We have license agreements with Bausch and Lomb for both the Vitrasert product for CMV retinitis and the Retisert product for posterior uveitis. We also have a license agreement with Alimera for ocular applications of the ILUVIEN device, including its use in DME. We have a collaboration agreement with Pfizer for the Durasert device delivering latanoprost for certain opthalmic diseases.
We have 2 FDA approved products, Vitrasert and Retisert. Both are being sold by Bausch and Lomb. ILUVIEN for DME received a positive outcome from the EU Decentralized Procedure and has subsequently received formal marketing authorization in the U.K., Austria, France, Germany,Portugal, Spain,Italy, Norway and Denmark.